Core Viewpoint - Smurfit Westrock PLC is set to report its first-quarter 2025 results on May 1, following the merger of Smurfit Kappa and WestRock in July 2024, with expectations of revenue growth and improved earnings per share [1][2]. Financial Estimates - The Zacks Consensus Estimate for first-quarter revenues is $7.85 billion, reflecting a 4.1% increase from the previous quarter [2]. - The earnings per share estimate is 65 cents, up from 34 cents in the prior quarter, with a 4.8% upward revision in the last 60 days [2]. - Adjusted EBITDA is projected at $1.25 billion for the first quarter of 2025 [4]. Segment Performance - The Europe, MEA, and APAC segment is expected to generate revenues of $2.61 billion, up from $2.52 billion in the fourth quarter, with adjusted EBITDA estimated at $418.6 million [6]. - North America segment revenues are estimated at $4.54 billion, slightly down from $4.59 billion, with adjusted EBITDA expected to rise to $755.3 million [7]. - The LATAM segment is projected to see revenues of $483.6 million, down from $524 million, with adjusted EBITDA estimated at $112.3 million [8]. Market Dynamics - Demand for corrugated packaging and containerboard remains stable, driven by e-commerce growth and the need for sustainable packaging solutions [3]. - However, increased costs related to recovered fiber, labor, and distribution, particularly in Europe, may negatively impact margins [4]. Earnings Prediction - The model indicates a potential earnings beat for Smurfit Westrock, supported by a positive Earnings ESP of +3.72% and a Zacks Rank of 3 [9]. Stock Performance - Smurfit Westrock's shares have decreased by 13.9% over the past six months, compared to a 4.5% decline in the industry [10].

Core Viewpoint - Floor & Decor Holdings, Inc. is expected to report an increase in revenue for the first quarter of 2025, with a consensus estimate of $1.16 billion, reflecting a 6.1% improvement from the previous year [1] Revenue and Earnings Estimates - The Zacks Consensus Estimate for first-quarter earnings per share is stable at 45 cents, indicating a decline of 2.2% from the same period last year [2] - The company has a trailing four-quarter earnings surprise average of 18.2%, with the last reported quarter exceeding estimates by 50% [2] Key Growth Drivers - The company's disciplined expansion strategy, supply chain agility, strategic investments, and merchandise innovation are expected to enhance market share [2] - A persistent supply-demand imbalance in housing and the increasing median age of owner-occupied homes are driving demand for home upgrades and remodeling, benefiting hard surface flooring and related categories [2] Product and Market Expansion - The launch of new product categories, including a semi-custom cabinet program in 40 warehouse stores and online, is anticipated to be a significant revenue catalyst [3] - By entering adjacent remodeling categories such as cabinets and outdoor products, the company is expanding its share of customer projects beyond flooring [3] Store Expansion Strategy - The disciplined approach to expanding the store footprint is a key driver of top-line growth, focusing on warehouse-format store openings in markets with existing brand awareness [4] - The strategic push to capture a larger share of the professional customer base is gaining traction [4] Sales Performance Concerns - A soft start to the first quarter is noted, with comparable store sales declining 1.7% as of February 20, indicating that momentum from the previous quarter may not have continued [5] - The company has diversified its sourcing away from China, reducing reliance from 50% in 2018 to 18% in 2024, although tariffs remain a challenge [5] Earnings Prediction Model - The current model does not predict a definitive earnings beat for Floor & Decor, as it holds a Zacks Rank of 3 and an Earnings ESP of 0.00% [6][7]

Core Viewpoint - McDonald's Corporation (MCD) is expected to report a decline in first-quarter 2025 earnings and revenues due to weak traffic and economic pressures on low-income consumers [2][4]. Financial Performance Expectations - The Zacks Consensus Estimate for first-quarter EPS has decreased to $2.64, reflecting a 2.2% drop from the previous year's EPS of $2.70 [2]. - Revenue estimates for the quarter are set at $6.08 billion, indicating a 1.4% year-over-year decline [2]. - U.S. revenues are projected to decline by 0.9% to $2,486.3 million, while revenues from International Operated Markets are expected to decrease by 0.7% to $2,927.1 million [3]. Factors Influencing Performance - Weak traffic, particularly in the U.S. and large international markets, is anticipated to negatively impact revenues [2]. - Economic pressures on low-income consumers have suppressed spending, affecting traffic and average check sizes [2]. - Despite the challenges, strong digital adoption, innovative menu offerings, and strategic unit expansion are expected to support performance [4]. Operational Insights - The company is likely to see a 1% increase in U.S. same-store sales and a 0.9% increase in International Operated Markets comps [5]. - Persistent pressure from elevated commodity prices and wages may have negatively impacted the operating margin during the quarter [5]. Earnings Prediction - The model predicts a potential earnings beat for McDonald's, supported by a positive Earnings ESP of +0.06% and a Zacks Rank of 3 (Hold) [6].

Core Viewpoint - Vertex Pharmaceuticals is expected to exceed revenue and earnings expectations in its upcoming first-quarter 2025 results, with projected revenues of $2.82 billion and earnings of $4.22 per share [1]. Group 1: Financial Performance - Year-to-date, Vertex's shares have increased by 23.3%, contrasting with a 5.2% decline in the industry [1]. - The Zacks Consensus Estimate for Trikafta/Kaftrio sales is $2.55 billion, while the company's model estimates it at $2.62 billion [3]. Group 2: Product Sales and Pipeline - Sales growth in Vertex's cystic fibrosis (CF) franchise is primarily driven by Trikafta/Kaftrio, particularly in younger demographics [3]. - Higher sales of Trikafta/Kaftrio may have led to a decline in sales of other CF drugs, including Symdeko, Orkambi, and Kalydeco [4]. - Vertex's gene therapy, Casgevy, approved for sickle cell disease and transfusion-dependent beta-thalassemia, generated $8 million in sales in the last quarter, with expectations for higher sales in Q1 2025 [5]. - The FDA approved Vertex's Journavx for moderate-to-severe acute pain in January 2025 [6]. - Alyftrek, a new CFTR modulator therapy, received FDA approval in December 2024 and is under review in the EU, with a positive opinion from the EMA [7]. Group 3: Upcoming Earnings Call Expectations - Investors are looking for updates on the commercial launch of Alyftrek and Journavx, as well as progress on other pipeline candidates targeting various diseases [8]. - Vertex has had a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 2.58% [9]. Group 4: Earnings Prediction - The model predicts an earnings beat for Vertex, supported by a positive Earnings ESP of +0.40% [10].

Core Viewpoint - Investors are keenly awaiting Exelixis' first-quarter 2025 results, particularly focusing on the performance of its lead drug, Cabometyx, with sales and earnings estimates at $502.8 million and 42 cents per share respectively [1] Group 1: Financial Performance - Exelixis has a history of earnings surprises, beating estimates in three of the last four quarters with an average surprise of 26.87%, including a 7.84% beat in the last reported quarter [1] - The Zacks Consensus Estimate for Cabometyx sales is $434 million, while the model estimate is $457.3 million, indicating strong sales performance [3] - Collaboration revenues have increased due to higher royalty revenues from cabozantinib sales outside the U.S., a trend expected to continue [4] Group 2: Product Developments - Cabometyx is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma, maintaining its status as the leading TKI for RCC [3] - Recent FDA approvals expanded Cabometyx's label for treating adult and pediatric patients with previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET) [5][6] Group 3: Share Repurchase and Financial Strategy - The board has authorized a $500 million stock repurchase program, expected to commence after completing the ongoing $500 million program [7] - Ongoing share repurchases are likely to positively impact the bottom line, although operating expenses may rise due to costs associated with a broader portfolio [7] Group 4: Earnings Prediction - The earnings model predicts a potential earnings beat for Exelixis, supported by a positive Earnings ESP of +7.14% and a Zacks Rank of 3 [8][9] - The Most Accurate Estimate for earnings is 45 cents per share, compared to the consensus estimate of 42 cents [9] Group 5: Stock Performance - Exelixis shares have gained 11.4% year-to-date, contrasting with a 3.7% decline in the industry [12]

Core Viewpoint - Incyte Corporation (INCY) is anticipated to exceed earnings estimates for Q1 2025, with revenue expected at $1.01 billion and earnings at $1.05 per share [1] Group 1: Revenue Drivers - Incyte's primary revenue source is from Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor, which is expected to maintain momentum across all approved indications [2] - The Zacks Consensus Estimate for Jakafi's sales in Q1 is projected at $661 million, with additional royalty revenues from Novartis for Jakafi's commercialization outside the U.S. [3][4] - Opzelura's sales are estimated at $127 million for Q1, driven by new patient starts and refills in the U.S. and contributions from the EU [7][6] Group 2: Competitive Landscape - Competition from other approved drugs may limit Jakafi's sales growth potential [2] - Novartis reported a 13% increase in Jakavi sales (the international name for Jakafi) in Q4 2024, indicating a positive trend likely to continue [4] Group 3: Additional Revenue Streams - Other drugs such as Minjuvi, Pemazyre, and Iclusig are also expected to contribute to Incyte's revenue, with sales estimates of $28.67 million for Iclusig, $33.43 million for Minjuvi, and $21.62 million for Pemazyre [9][8] - Incyte's recent acquisition of tafasitamab provides exclusive global rights, further enhancing its product portfolio [8] Group 4: New Product Launches - The FDA approved Niktimvo (axatilimab-csfr) for GVHD, marking Incyte's second approved treatment for chronic GVHD, with sales updates anticipated during the earnings announcement [10] Group 5: Financial Outlook - Management indicates that 2025 is expected to be a transformational year for Incyte, with multiple product launches and clinical milestones, although operating expenses are likely to rise due to increased R&D and administrative costs [11] - Incyte has a history of disappointing earnings surprises, missing estimates in the last four quarters with an average negative surprise of 92.90% [12] Group 6: Earnings Predictions - The Earnings ESP for Incyte is +12.17%, with the most accurate estimate at $1.18, suggesting a potential earnings beat [14]

Core Insights - The oil/energy sector is experiencing significant challenges in Q1 2025 due to fluctuating commodity prices and market uncertainties, with oil prices declining and natural gas prices increasing, creating a mixed environment for companies in this sector [1] Oil Price Performance - In Q1 2025, the average price of West Texas Intermediate crude fell to $71.84 per barrel, down from $77.56 in the previous year, driven by concerns over weaker global economic growth, increased supply from non-OPEC+ nations, and lower-than-expected demand [2] - Escalating trade tensions and rising oil inventories further pressured oil prices [2] Natural Gas Price Trends - Natural gas prices increased significantly, with the Henry Hub spot price averaging $4.15 per million British thermal units (MMBtu), up from $2.13 per MMBtu in the prior-year quarter, primarily due to colder weather boosting heating demand and rising LNG exports [3] Earnings Outlook for Oil/Energy Sector - Oil/energy companies in the S&P 500 are projected to report an 11.1% year-over-year earnings decline for Q1 2025, continuing a downward trend from the previous quarter [4] - In contrast, the broader S&P 500 is expected to see a 6.8% earnings increase, highlighting the underperformance of the oil/energy sector [5] Revenue Trends - Revenue for oil/energy companies is projected to decline by 0.4% year-over-year, while S&P 500 revenues are on track to grow by 3.9%, indicating struggles in maintaining top-line growth in a changing commodity environment [6] Margin Compression - The earnings drag from lower oil prices continues to dominate despite higher natural gas prices, compressing margins and making it difficult for companies to deliver consistent results [7][9] Sector Performance Comparison - Other sectors, such as Technology (+12.5%), Medical (+34.7%), and Utilities (+14.1%), are experiencing strong earnings growth, while the oil/energy sector remains the worst performer alongside other weak sectors like autos and basic materials [8] Company-Specific Earnings Insights - TechnipFMC plc (FTI) has an Earnings ESP of -0.92% and a Zacks Rank 3, indicating low chances of an earnings beat, with a consensus estimate of 36 cents per share, suggesting a 63.64% increase from the prior year [11][13] - Valero Energy Corporation (VLO) has an Earnings ESP of -14.71% and a Zacks Rank 3, with a consensus estimate of 43 cents per share, indicating an 88.74% decrease from the prior year [13] - RPC, Inc. (RES) has an Earnings ESP of 0.00% and a Zacks Rank 3, with a consensus estimate of 7 cents per share, suggesting a 46.15% decrease from the prior year [14][15] - CNX Resources Corporation (CNX) has an Earnings ESP of -2.96% and a Zacks Rank 3, with a consensus estimate of 65 cents per share, indicating a 44.44% increase from the prior year [16][17]

Core Viewpoint - Agnico Eagle Mines Limited (AEM) is expected to report strong first-quarter 2025 results driven by higher gold prices and robust production levels [1][5]. Financial Performance - The Zacks Consensus Estimate for first-quarter earnings is $1.43 per share, reflecting an 88.2% year-over-year increase [2]. - Revenue estimates stand at $2.24 billion, indicating a 22.4% rise year-over-year [2]. - AEM has consistently beaten earnings estimates in the past four quarters by an average of approximately 16.4% [3]. Production and Costs - AEM's realized gold prices are estimated at $2,655 per ounce for the quarter, representing a 28.8% year-over-year increase [6]. - Payable gold production is projected at 844,808 ounces for the first quarter, supported by increased mill throughput and productivity improvements [7]. - Total cash costs per ounce are forecasted between $915 and $965, with all-in-sustaining costs (AISC) expected between $1,250 and $1,300 for 2025, indicating year-over-year increases [8]. Market Conditions - Gold prices have surged nearly 19% in the first quarter and are up about 26% year-to-date, driven by safe-haven demand amid global trade tensions and economic uncertainties [5]. - AEM's AISC is estimated at $1,217 per ounce, reflecting a 2.2% year-over-year increase [9]. Stock Performance and Valuation - AEM's shares have increased by 96.2% over the past year, outperforming the Zacks Mining – Gold industry and the S&P 500 [10]. - The company is currently trading at a forward 12-month earnings multiple of 24.24X, which is a 43.9% premium to the peer group average of 16.84X [13]. Growth Prospects - AEM is positioned for growth through key projects like Odyssey, Detour Lake, and Hope Bay, which are expected to enhance production and cash flows [15]. - The merger with Kirkland Lake Gold has established AEM as a leading senior gold producer with a strong pipeline of development projects [15][16]. - AEM's strong liquidity and cash flow generation support its exploration budget and debt management, enhancing shareholder value [16]. Investment Thesis - AEM stock is considered a compelling investment opportunity due to its growth projects, financial health, and favorable market conditions for gold [17].

Core Viewpoint - PulteGroup Inc. is expected to report a decline in revenues and earnings per share for the first quarter of 2025, primarily due to ongoing affordability challenges in the housing market and high mortgage rates impacting homebuyers [4][5][6]. Revenue Summary - The Zacks Consensus Estimate for Q1 2025 revenues is $3.86 billion, indicating a 2.2% year-over-year decline [3]. - Homebuilding revenues are projected to decrease 0.8% year over year to $3.83 billion, while financial services revenues are expected to increase 2.4% year over year to $94.6 million [6]. - Home closings are anticipated to be between 6,400 and 6,800 units, down from 7,095 units a year ago, with a model prediction of 6,754 units, reflecting a 4.8% decline [5]. Earnings Summary - The Zacks Consensus Estimate for EPS has decreased to $2.47 from $2.48, representing a 13.9% decrease from the year-ago EPS of $2.87 [2]. - The company expects home sales gross margins to be approximately 27%, down from 29.6% reported in the previous year, with predicted homebuilding gross margins of 26.7%, a decrease of 260 basis points [9]. Orders and Backlogs - Net new orders are expected to increase 4.4% year over year to 8,752 units, while total backlog is projected to decline 9.5% to 12,151 units, with a total backlog value decrease of 6% year over year to $7.71 billion [11]. Market Dynamics - The company is facing significant margin pressure due to the need for incentives to manage affordability concerns while maintaining profitability, although cost-saving efforts may mitigate some risks [8]. - PulteGroup's pricing strategy aims to balance affordability challenges and shifting market dynamics, with an expected average selling price (ASP) for the quarter between $560,000 and $570,000, up from $538,000 a year ago [7].

Core Viewpoint - Danaher Corporation is expected to report a decline in both revenue and earnings for the first quarter of 2025, with revenues estimated at $5.56 billion, a decrease of 4.2% year-over-year, and earnings per share projected at $1.62, down 15.6% from the previous year [1]. Group 1: Financial Estimates - The Zacks Consensus Estimate for revenues is $5.56 billion, indicating a 4.2% decrease from the same quarter last year [1]. - The consensus estimate for earnings is $1.62 per share, reflecting a 15.6% decline compared to the year-ago quarter [1]. - In the last reported quarter, the company's bottom line missed the Zacks Consensus Estimate by 1.4%, but it had an average earnings surprise of 7.4% over the last four quarters [2]. Group 2: Segment Performance - The Diagnostics segment is expected to see a revenue decrease of 7% year-over-year to $2.35 billion, despite strength in molecular diagnostics driven by increased testing [3]. - The Life Sciences segment is facing challenges due to sluggish demand in pharma and biotech markets in China, leading to a decline in sales across various instrument businesses [4]. - The genomics consumables business is also expected to decline by 6.9% year-over-year to $1.62 billion due to weak sales in gene reading and protein product lines [5]. - Conversely, the Biotechnology segment is projected to grow by 4.1% year-over-year to $1.59 billion, supported by strong demand for bioprocessing and consumables [6]. Group 3: Strategic Developments - Danaher acquired Abcam plc in December 2023, enhancing its Life Sciences segment with a strong portfolio of protein consumables [7]. - The company is experiencing rising costs of sales, which may negatively impact profitability, alongside foreign currency headwinds due to its international market exposure [8]. Group 4: Earnings Prediction - The company has an Earnings ESP of +0.33%, with the Most Accurate Estimate at $1.63 per share, suggesting a potential earnings beat [10].